BamSEC and AlphaSense Join Forces
Learn More

Vyome Holdings Inc. – Material Contracts

NASDAQ: HIND    
Share price (9/22/26): $1.95    
Market cap (9/22/26): $13.7 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 9 pages Consulting Agreement
12/34/56
EX-10.1
from 10-Q 21 pages Exclusive License Agreement
12/34/56
EX-10.45
from 10-K 2 pages Amendment No. 1 to Notes Purchase and Exchange Agreement
12/34/56
EX-10.23
from 10-K 2 pages Amendment to Employment Agreement, Dated July 8, 2024, by and Between Reshape Lifesciences Inc
12/34/56
EX-10.22
from 10-K 2 pages Office Service Agreement Dated June 27, 2024 Between Regus Management Group, LLC and Vyome Therapeutics, Inc
12/34/56
EX-10.21
from 10-K 2 pages Renewal Service Agreement Dated May 23, 2024 Between Regus Management Group, LLC and Vyome Therapeutics, Inc
12/34/56
EX-10.1
from 8-K 35 pages Notes Purchase and Exchange Agreement by and Among Livechain, Inc.; Lich Ai, Inc. and Remus Capital Series B II, L.P
12/34/56
EX-10.1
from 8-K 5 pages December 17, 2025 Attn: Venkat Nelabhotla Co-Founder, President & CEO Vyome Holdings, Inc Harvard Square, One Mifflin Place Suite 400, Cambridge Ma 02138 USA via Email: ALISON.FORSYTHE@HUMANYZE.com Re: Binding Letter of Intent Dear Mr. Nelabhotla
12/34/56
EX-10.1
from 8-K 8 pages Interim Full-Time Chief Financial Officer Consulting Agreement
12/34/56
EX-10.1
from 8-K 4 pages Vyome Therapeutics, Inc. Promissory Note
12/34/56
EX-10.1
from 8-K 21 pages Placement Agency Agreement June 8, 2025
12/34/56
EX-10.40
from S-4/A 17 pages License and Non-Stocking Distribution Agreement
12/34/56
EX-10.1
from 425 5 pages Vyome Therapeutics, Inc. Promissory Note
12/34/56
EX-10.1
from 8-K 5 pages Vyome Therapeutics, Inc. Promissory Note
12/34/56
EX-10.8
from 10-K 22 pages ReShape Lifesciences Employment Agreement
12/34/56
EX-10.27
from S-1/A 38 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 5 pages Re: Amendment No. 1
12/34/56
EX-10.26
from S-1 44 pages Equity Purchase Agreement
12/34/56
EX-10.32
from S-4/A 18 pages Development & Licensing Agreement
12/34/56
EX-10.31
from S-4/A 3 pages Addendum to Supply and Marketing Agreement
12/34/56